Business segment information (Tables)

6 Months Ended

Jun. 30, 2014

Segment Reporting [Abstract]

Schedule of External Net Sales by SBU Reporting Segment

The table below presents external net sales by SBU reporting segment (amounts reported for prior periods have been reclassified to conform to the new segment reporting structure). Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of fees earned for the marketing of Trinity Evolution^®, Trinity ELITE^® and Versashield™ in the Biologics segment.

	External Net Sales by SBU
	Three Months Ended June 30,
(U.S. Dollars, in thousands)	2014		2013		Reported Growth			Constant Currency Growth
			(Restated)		(Restated)			(Restated)
BioStim	$	39,513	$	37,948		4	%		4	%
Biologics		13,853		13,240		5	%		5	%
Extremity Fixation		27,303		23,210		18	%		14	%
Spine Fixation		20,316		23,242		(13	)%		(13	)%
Total Net Sales	$	100,985	$	97,640		3	%		3	%

	External Net Sales by SBU
	Six Months Ended June 30,
(U.S. Dollars, in thousands)	2014		2013		Reported Growth			Constant Currency Growth
			(Restated)		(Restated)			(Restated)
BioStim	$	76,650	$	75,174		2	%		2	%
Biologics		26,863		26,600		1	%		1	%
Extremity Fixation		54,369		49,407		10	%		9	%
Spine Fixation		43,117		48,738		(12	)%		(12	)%
Total Net Sales	$	200,999	$	199,919		1	%		—	%

Summary of Net Margin, Defined as Gross Profit Less Sales and Marketing Expenses from Continuing Operations by SBU Reporting Segment

The table below presents net margin, defined as gross profit less sales and marketing expenses, from continuing operations by SBU reporting segment:

Net margin by SBU	Three Months Ended June 30,						Six Months Ended June 30,
(U.S. Dollars, in thousands)	2014			2013			2014			2013
				(Restated)						(Restated)
Net margin:
BioStim	$	17,706		$	18,035		$	32,726		$	35,218
Biologics		6,496			5,706			12,997			11,725
Extremity Fixation		6,656			5,250			13,590			10,891
Spine Fixation		3,130			2,708			7,189			4,883
Corporate		(430	)		(482	)		(874	)		(906	)
Total net margin		33,558			31,217			65,628			61,811
General and administrative		17,553			15,181			34,829			33,422
Research and development		6,313			8,551			12,246			14,292
Amortization of intangible assets		661			565			1,245			1,109
Costs related to the accounting review and restatement		2,327			—			10,633			—
Operating income	$	6,704		$	6,920		$	6,675		$	12,988